Supreme Court Preserves Access to Abortion Pill Mifepristone Amid Ongoing Lawsuit

The U.S. Supreme Court has issued an order preserving women's access to mifepristone, the most widely used medication for abortion, while legal challenges continue. The decision rejects lower-court restrictions that would have mandated in-person doctor visits and halted mail-order distribution of the drug. This emergency relief allows uninterrupted access at least until next year as the case proceeds through potential appeals. The lawsuit, initiated by Louisiana, argues that current FDA regulations undermine state abortion bans and question the drug's safety, despite longstanding FDA determinations of its efficacy. Anti-abortion groups are pressuring the Trump administration to accelerate regulatory reviews to restrict telehealth prescriptions, creating political tension for the Republican leadership. Meanwhile, medical groups and pharmaceutical companies warn that limiting access could disrupt the broader drug approval process. The Court's action follows a similar dispute three years ago, where it ultimately dismissed a challenge from anti-abortion physicians on standing grounds. The Biden-era FDA had previously eased restrictions, but the current political climate remains charged as both sides interpret the federal government's silence in this case as significant.